Protagenic Therapeutics receives Nasdaq delisting notice; stock suspension set for Nov 29

Protagenic Therapeutics, Inc.new

Failed to meet Nasdaq's minimum $2.5M stockholders' equity requirement by Nov 18, 2024, after extension.
Nasdaq delist determination letter received Nov 19; trading of PTIX stock to suspend on Nov 29 unless appeal.
Company may request Nasdaq hearing to stay delisting, but no assurance of regaining compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.